Business

Add as a preferred source on Google

Valeritas to Release Third Quarter 2016 Financial Results and Host Conference Call on Thursday, November 10, 2016

BRIDGEWATER, N.J., Oct. 20, 2016 -- Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that the Company will release its third quarter 2016 financial results on Thursday, November 10, 2016 after the market closes. Val…

2 min read
EconoTimes — Reading the Times. Understanding the Future.

Read the original article

BRIDGEWATER, N.J., Oct. 20, 2016 -- Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that the Company will release its third quarter 2016 financial results on Thursday, November 10, 2016 after the market closes.

Valeritas will hold a conference call on Thursday, November 10, 2016 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The dial-in numbers are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers. The conference ID number is 93887928. A live webcast of the conference call will be available on the investor relations page of the Valeritas corporate website at www.valeritas.com.

After the live webcast, a replay of the webcast will remain available online until the Company reports fourth quarter 2016 financial results on the investor relations page of the Valeritas corporate website, www.valeritas.com. In addition, a telephonic replay of the call will be available through November 12, 2016. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers.  Please use the replay pin number 93887928.

About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas’ flagship product, V-Go® Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.

Investor Contacts:
Nick Laudico / Robert Flamm, Ph.D.
The Ruth Group
(646)536-7030 / 7017
IR@valeritas.com

Or

The Del Mar Consulting Group, Inc.
Robert B. Prag, President
858-794-9500
bprag@delmarconsulting.com

Media Contact:
Christopher Hippolyte
The Ruth Group
(646)536-7023
PR@valeritas.com

Related articles

View all
Business

Kimberly-Clark Stock Rises as Q3 Earnings Beat Estimates

Kimberly-Clark (NASDAQ: KMB) shares gained 1.8% on Thursday morning after the consumer products manufacturer reported preliminary third-quarter 2026 financial results that exceeded Wall Street expectations for both reven…